VDM 11

• CAT Number: I010404
• CAS Number: 313998-81-1
• Molecular Formula: C27H39NO2
• Molecular Weight: 409.60
• Purity: ≥95%
• Synonyms: (5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide
• Target: Cannabinoid Transporters
• Solubility: Soluble in ethanol (supplied pre-dissolved in anhydrous ethanol, 5mg/ml)
• Storage: Desiccate at -20°C
• IUPAC Name: (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)icosa-5,8,11,14-tetraenamide
• InChI: InChI=1S/C27H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-27(30)28-26-22-21-25(29)23-24(26)2/h7-8,10-11,13-14,16-17,21-23,29H,3-6,9,12,15,18-20H2,1-2H3,(H,28,30)/b8-7-,11-10-,14-13-,17-16-
• InChIKey: WUZWFRWVRHLXHZ-ZKWNWVNESA-N
• SMILES: CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=C(C=C(C=C1)O)C

VDM-11（Cat No.:I010404）is a synthetic compound investigated for its potential in treating neurodegenerative diseases, particularly Alzheimer’s disease. It functions as a modulator of certain biochemical pathways involved in neuroprotection and cognitive function. VDM-11 has been studied for its ability to inhibit amyloid-beta aggregation, a key hallmark of Alzheimer’s pathology. By interfering with the accumulation of amyloid plaques, it aims to reduce neuroinflammation and improve neuronal function. Although preclinical studies have shown promise, further clinical trials are needed to evaluate its safety, efficacy, and therapeutic potential in Alzheimer’s and other neurodegenerative conditions.